Back to search

Article

Can a three months treatment with oral Desogestrel prior to insertion of the etonogestrel subdermal implant improve continuation rate at one year? A randomized trial

2022-08-01

Abstract excerpt

<title>Abstract</title> <p><bold>Objective: </bold>The aim of our study is to evaluate<bold> </bold>if daily oral 75µg of Desogestrel (DSG) for 3 months prior to the insertion of etonogestrel subdermal implant (ENG-IMPLANT) might help reduce its premature discontinuation.<bold>Results: </bold>A total of 66 women were randomized in the ENG-IMPLANT group (26) and in the DSG+ENG-IMPLANT group (40), respectively, in...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
7d7e8dcf-366d-59bb-a572-b57ad453def0
DOI
10.21203/rs.3.rs-1815840/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 8 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Can a three months treatment with oral Desogestrel prior to insertion of the etonogestrel subdermal implant improve continuation rate at one year? A randomized trialDOI 10.21203/rs.3.rs-1815840/v1
Factors influencing continuation of combined oral contraceptives in women with dysmenorrhea or endometriosis: A retrospective cohort study utilizing a claims database in JapanSemantic proximity
Acceptability and satisfaction of contraceptive vaginal rings in clinical studies: a systematic review and narrative synthesisSemantic proximity
Patient-reported outcomes after switching from brand-name to generic drospirenone/ethinylestradiol combined oral contraceptives: a questionnaire-based observational studySemantic proximity
Pharmacokinetic bioequivalence between Nuvaring® (etonogestrel/ethinylestradiol 11.7/2.7 mg) and Ornibel Premium® (etonogestrel/ethinylestradiol 8.25/2.6 mg), a novel polymer composition contraceptive vaginal ringSemantic proximity
Clinical use of Anti-Müllerian Hormone to Monitor Resumption of Ovarian Activity following Removal of a 4.7 mg Deslorelin Implant in Queens.Semantic proximity
Real Life Data for Relugolix/Estradiol/Norethisteroneacetate Treatment for Chronic Pelvic Pain in Endometriosis PatientsSemantic proximity
A 10-year follow‐up on the practice of luteal phase support using worldwide web‐based surveysSemantic proximity
Comparative efficacy and safety of modern treatment modalities for Genitourinary Syndrome of Menopause (GSM): A Systematic Review and Network Meta-analysis of RCTsSemantic proximity
Select a neighboring publication to make it the new centre.